chartexchange

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. | Nov 3, 2026 4:15 PM EST

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ®  Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

Read original article